




# DISCUSSION OF BRUKINSA FOR ADULT PATIENTS WITH CLL/SLL

## ABOUT

Join us for an informative case-based discussion on the use of BRUKINSA® for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The discussion will include the results from the latest BRUKINSA head-to-head clinical trial as well as information on dosing, administration, and patient support.

Healthcare professionals including Hematologist-Oncologists and Medical Oncologists are encouraged to participate in this interactive dialogue.

This non-CME program is developed and offered by BeiGene, Ltd. This is not an official program of the Cleveland Clinic.


 DATE & TIME

**November 1, 2024**  
12:00 PM

 LOCATION


**Margaritaville Hollywood Beach Resort**  
1111 North Ocean Drive  
Hollywood, FL 33019

 SPEAKER



**Moshe Levy, MD**  
*Director, Hematologic Malignancies*  
Baylor University Medical Center  
Dallas, TX

TO RSVP:



Please scan the QR Code with your mobile device.

Or by contacting:  
Darwin Torres-Portalatin  
(954) 732-9933  
darwin.torres-portalatin@beigene.com

## INDICATIONS

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:

- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

## IMPORTANT SAFETY INFORMATION

### Warnings and Precautions

**Hemorrhage:** Fatal and serious hemorrhage has occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher hemorrhage, including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax was reported on 3.8% of patients treated with BRUKINSA in clinical trials, with fatalities occurring in 0.2% of patients. Bleeding of any grade, excluding purpura and petechiae, occurred in 32% of patients.

In accordance with the updated PhRMA Code, BeiGene is no longer able to provide alcohol as part of this educational program.

Participants can purchase their own alcoholic beverages directly from the venue.

Spouses and other guests who are not healthcare professionals may not attend this event. Please be aware that if you are a licensed US physician, the meal associated with this program is reportable under the Federal Open Payments/Sunshine Act. State laws and federal entities may restrict your ability to receive meals offered in connection with this event. You are responsible for complying with any restrictions or limitations related to such requirements.

## IMPORTANT SAFETY INFORMATION (CONT.)

### Warnings and Precautions (cont.)

Bleeding has occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Coadministration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.

Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding.

**Infections:** Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher infections occurred in 26% of patients, most commonly pneumonia (7.9%), with fatal infections occurring in 3.2% of patients. Infections due to hepatitis B virus (HBV) reactivation have occurred.

Consider prophylaxis for herpes simplex virus, pneumocystis jirovecii pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.

**Cytopenias:** Grade 3 or 4 cytopenias, including neutropenia (21%), thrombocytopenia (8%) and anemia (8%) based on laboratory measurements, developed in patients treated with BRUKINSA. Grade 4 neutropenia occurred in 10% of patients, and Grade 4 thrombocytopenia occurred in 2.5% of patients.

Monitor complete blood counts regularly during treatment and interrupt treatment, reduce the dose, or discontinue treatment as warranted. Treat using growth factor or transfusions, as needed.

**Second Primary Malignancies:** Second primary malignancies, including non-skin carcinoma, have occurred in 14% of patients treated with BRUKINSA. The most frequent second primary malignancy was non-melanoma skin cancers (8%), followed by other solid tumors in 7% of the patients (including melanoma in 1% of patients) and hematologic malignancies (0.7%). Advise patients to use sun protection and monitor patients for the development of second primary malignancies.

**Cardiac Arrhythmias:** Serious cardiac arrhythmias have occurred in patients treated with BRUKINSA. Atrial fibrillation and atrial flutter were reported in 4.4% patients treated with BRUKINSA, including Grade 3 or higher cases in 1.9% of patients. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher ventricular arrhythmias were reported in 0.3% of patients.

Monitor for signs and symptoms of cardiac arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea, chest discomfort), manage appropriately, and consider the risks and benefits of continued BRUKINSA treatment.

**Hepatotoxicity, Including Drug-Induced Liver Injury:** Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including BRUKINSA.

Evaluate bilirubin and transaminases at baseline and throughout treatment with BRUKINSA. For patients who develop abnormal liver tests after BRUKINSA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold BRUKINSA. Upon confirmation of DILI, discontinue BRUKINSA.

**Embryo-Fetal Toxicity:** Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for 1 week after the last dose. Advise men to avoid fathering a child during treatment and for 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

### Adverse Reactions

The most common adverse reactions in  $\geq 30\%$ , including laboratory abnormalities, in patients who received BRUKINSA (N=1729) are decreased neutrophil count (51%), decreased platelet count (41%), upper respiratory tract infection (38%), hemorrhage (32%) and musculoskeletal pain (31%).

### Drug Interactions

**CYP3A Inhibitors:** When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.

**CYP3A Inducers:** Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment may be recommended with moderate CYP3A inducers.

### Specific Populations

**Hepatic Impairment:** The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.

**Please see full Prescribing Information for BRUKINSA (zanubrutinib).**